Prognostic significance of nuclear hepatoma-derived growth factor expression in gallbladder cancer

Table 4 Univariate log-rank analysis of disease-specific survival

Parameter	Category	Cases (n)	Mean survival time (mo) 95%CI	P value
Age	< 60	8	14.8 (4.3-25.2)	0.930
	≥ 60	32	14.3 (9.2-19.4)
Sex	Male	11	20.2 (10.4-30.1)	0.142
	Female	29	12.7 (7.9-17.5)
Histopathological subtypes	High	8	30.4 (21.5-39.2)	0.003
	Middle	14	12.1 (5.6-18.5)
	Low	18	7.2 (4.8-9.7)
TNM stage	0-I	5	36.0 (36.0-36.0)	0.015
	II-IV	35	11.4 (7.4-15.4)
Lymph node metastasis	Negative	19	19.4 (11.4-27.4)	0.005
	Positive	21	9.1 (4.4-13.8)
Perineural invasion	Absent	12	27.6 (18.3-37.0)	0.013
	Present	28	10.3 (6.3-14.2)
HDGF	Negative	9	32.1 (22.1-42.2)	0.001
	Positive	31	9.6 (6.1-13.1)

HDGF: Hepatoma-derived growth factor; TNM: Tumor node metastasis.